Highest-materiality recent filing
Intellia reports positive Phase 3 HAELO data for lonvo-z; BLA submission expected H2 2026
Phase 3 HAELO trial met primary endpoint: lonvo-z reduced HAE attacks by 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
Intellia reports positive Phase 3 HAELO results for lonvo-z; BLA rolling submission initiated
89% reduction (p<0.0001) in monthly attacks requiring on-demand treatment vs placebo; 91% reduction in moderate/severe attacks.
Intellia Q1 loss narrows; Phase 3 HAE data positive, rolling BLA initiated
Net loss $96.2M vs $114.3M YoY; revenue $15.0M (down from $16.6M).
Offered 16,744,187 shares at $10.75/share; underwriters exercised full option for 2,511,628 additional shares; net proceeds ~$194.6M.
Single dose of lonvo-z reduced HAE attacks by 87% vs placebo (mean monthly rate 0.26 vs 2.10, p<0.0001) over 6 months.
Intellia FDA lifts clinical hold on nex-z MAGNITUDE Phase 3 trial for ATTR-CM
FDA removed clinical hold on MAGNITUDE Phase 3 trial of nex-z for ATTR-CM after Grade 4 liver event on Oct 29, 2025.
Intellia Q4 net loss $95.8M; lonvo-z Phase 3 data mid-2026; nex-z clinical hold remains for ATTR-CM
Q4 2025 net loss $95.8M vs $128.9M Q4 2024; cash $605.1M, expected to fund operations into H2 2027.
FDA lifts clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for ATTRv-PN; MAGNITUDE hold ongoing
FDA removed clinical hold on IND for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv-PN, imposed Oct 29, 2025 after Grade 4 liver event and patient death.
Intellia provides update on FDA clinical hold for nex-z after patient death in MAGNITUDE trial
Patient in MAGNITUDE Phase 3 trial for ATTR-CM died from septic shock secondary to perforated duodenal ulcer; autopsy supports clinical diagnoses.
Lonvo-z pooled Phase 1/2: 97% (31/32) attack-free and LTP-free; 75% attack-free for ≥7 months (up to 32 months).
Intellia reports patient death in nex-z trial; awaits FDA clinical hold; lonvo-z on track
Patient who had Grade 4 liver transaminase elevations after nex-z dose in MAGNITUDE Phase 3 trial died; FDA clinical hold letter pending.
FDA places clinical hold on NTLA's Phase 3 nex-z trials after Grade 4 liver event
FDA verbally informed Intellia of clinical hold on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z (nexiguran ziclumeran).
Intellia pauses dosing in Phase 3 MAGNITUDE trials after Grade 4 liver event in one patient
Patient dosed on Sept 30, 2025, experienced Grade 4 liver transaminases and increased total bilirubin on Oct 24.
Mean serum TTR reduction of 92% at 24 months (n=33) and 90% at 36 months (n=12) after single dose.
Intellia Q2 net loss narrows to $101.3M; Phase 3 enrollment ahead; CMO to retire in 2026
Net loss $101.3M in Q2 2025 vs $147.0M a year ago; collaboration revenue $14.2M (up from $6.9M).
Intellia reports 98% reduction in HAE attacks with lonvo-z over 3 years in Phase 1
Single dose led to mean 98% reduction in monthly HAE attack rate across all 10 patients.
Intellia Therapeutics provides Phase 3 updates for NTLA-2002 and nex-z studies
HAELO study enrollment on track; expect completion Q3 2025, BLA submission H2 2026, potential US launch 2027.
Intellia announces positive two-year Phase 1 data for nex-z in ATTRv-PN with durable TTR reduction
Mean serum TTR reduction of 90% by Day 28 remained virtually unchanged for at least 24 months in 33 patients.
Intellia Q1 net loss $114.3M, cash $707.1M; Phase 3 HAE enrollment on track
Net loss $114.3M vs $107.4M in Q1 2024; collaboration revenue $16.6M down from $28.9M.
Intellia Q4 net loss $128.9M; cuts workforce 27%, ends NTLA-3001
Q4 2024 net loss $128.9M vs $132.2M prior year; revenue $12.9M.
Intellia signs 12-year Cambridge lease for ~147K sq ft; terminates Waltham lease with $78M payment
New lease at 400 Technology Square, Cambridge: initial 101K sq ft, expandable to ~147K sq ft in two tranches starting Dec 2027.
Preliminary cash, cash equivalents and investments of $862M as of Dec 31, 2024.
Intellia Phase 1 in vivo CRISPR therapy nex-z shows disease stabilization in ATTR amyloidosis
Single dose of nex-z achieved mean 90% serum TTR reduction at month 12 in ATTR-CM (n=36); sustained >24 months.
Intellia Q3 net loss $135.7M; cash $944.7M; FDA clears Phase 3 for nex-z polyneuropathy
Net loss $135.7M vs $122.2M YoY; cash $944.7M (down from $1.0B at Dec 31).
Mean monthly attack rate reduced by 77% (50 mg) vs placebo during weeks 1-16; 81% during weeks 5-16.
Intellia Q2 net loss widens to $147M; NTLA-2002 Phase 2 meets endpoints, Phase 3 on track
NTLA-2002 Phase 2 for HAE met primary and all secondary endpoints; 50 mg dose selected for pivotal Phase 3, on track to start 2H 2024.
Intellia Therapeutics appoints Edward Dulac as CFO; Glenn Goddard steps down June 30, 2024
Edward Dulac appointed EVP, CFO, and Treasurer, effective July 22, 2024.
Intellia Q1 net loss $107M; cash $953M; Phase 3 enrollment ahead; FDA alignment on ATTRv-PN trial
Net loss of $107.4M for Q1 2024; collaboration revenue $28.9M (up from $12.6M YoY) on $21M non-cash adjustment.
On March 19, 2024, Intellia gave notice to Regeneron to exit the Factor IX Co-Development and Co-Funding Agreement, effective after 180 days.
Intellia Therapeutics expands ATM equity facility from $400M to $750M
Intellia increased at-the-market equity offering facility from $400M to $750M via amendment to Jefferies Sales Agreement.
Intellia reports Q4 net loss $132.2M; cash $1.0B; on track for Phase 3 NTLA-2001 in Q1 2024
Q4 2023 net loss $132.2M vs $113.4M YoY; R&D expenses rose $9.0M to $109.0M.
Intellia reports NTLA-2002 Phase 1 data: 95% reduction in HAE attacks; 9/10 attack-free
Single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate across all 10 patients.
Intellia Therapeutics provides strategic update, cash ~$1.0B, workforce reduction of ~15%
Cash, cash equivalents and marketable securities ~$1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
Intellia reports Q3 net loss $122.2M, FDA clears NTLA-2001 Phase 3 IND for ATTR-CM
FDA cleared IND for NTLA-2001 Phase 3 MAGNITUDE trial in ATTR cardiomyopathy; on track to initiate by year-end.
Median serum TTR reduction of 91% and median residual TTR of 17 µg/mL at day 28 across 62 patients (doses ≥0.3 mg/kg).
FDA clears Intellia's IND for NTLA-2001 Phase 3 trial in ATTR cardiomyopathy
First-ever in vivo CRISPR candidate to enter late-stage clinical development (Phase 3).
Regeneron and Intellia expand CRISPR collaboration to neurological and muscular diseases
Uses Regeneron's antibody-targeted AAV vectors and Intellia's Nme2CRISPR/Cas9 for in vivo delivery.
NTLA-2002 Phase 1 data: 95% mean HAE attack reduction; 9 of 10 patients attack free
Single 25-75 mg dose of NTLA-2002 (n=10) produced 95% mean reduction in monthly HAE attack rate through median 9-month follow-up.
Intellia dosed first patient in NTLA-2002 Phase 2; Q1 net loss $103.1M, cash $1.2B
Dosed first patient in global Phase 2 study of NTLA-2002 for HAE; enrollment completion expected 2H 2023.
Laura Sepp-Lorenzino, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer (“CSO”), will retire from the Company and that her anticipated retirement date is December 31, 2025.
effective January 13, 2025, Dr. Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company.
Birgit Schultes, Ph.D. will become the Company’s Executive Vice President and CSO, effective as of January 13, 2025.
Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.
the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.
the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.
On June 12, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Brian Goff, as a Class I director, effective as of June 13, 2024, with a term expiring at the 2026 annual meeting of stockholders.
On April 10, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) appointed Michael P. Dube, 46, as principal accounting officer of the Company.
On December 5, 2023, John F. Crowley notified Intellia Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 5, 2023.
On June 5, 2023, Jean-François Formela notified Intellia Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.
the Board appointed Bill Chase, M.B.A., as a Class III director, with a term expiring at the 2025 annual meeting of stockholders.
On March 23, 2023, Caroline Dorsa notified Intellia Therapeutics, Inc. (the “Company”) of her intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.
Max materiality 0.95 · Median 0.72 · Most common event other_material